Three BCI companies raised over $500M in 12 months. Synchron, Neuralink, and Paradromics are crossing from clinical trials into commercial deployment — and defence teleoperation is the next frontier for neural control of drones and robotic systems.
Eighty percent of the human proteome is classified as undruggable. The surfaces are smooth. The binding pockets are missing. Conventional small molecules slide off them like water off wax. In the first half of 2026 alone, more than €8 million in seed and early-stage capital flowed into a single
Acodyne raises €2.5M: autonomous cargo drones are crossing from commercial delivery into defence resupply, as $8B pours into military robotics.
NUS researchers built a self-training platform that strengthens lab-grown muscle tissue around the clock, powering OstraBot to a record 467 mm/min — the fastest skeletal muscle-driven biohybrid robot ever reported.
Apeiron Labs raised $9.5M to deploy swarms of low-cost autonomous underwater vehicles (AUVs). The compact cloud-connected drones dive 400m, sampling temperature and acoustics for defense and civilian customers.
EdgeCortix's SAKURA-II becomes the first edge AI chip to pass NASA heavy ion testing, earn a DIU Success Memorandum, and complete US Air Force flight validation — 60 TOPS at 8W for orbital and tactical edge inference.
The FDA needs patient data to approve drugs. Rare-disease patients have the least data. That contradiction is why synthetic data is now gaining regulatory traction — and changing the economics of orphan-drug development.
An AI copilot for robotic surgery completed its first live clinical demonstration in Ghent. The surgical robotics market reached $18.3B, with AI-enabled systems capturing 35% of new installations. At least four research groups now field working prototypes.